Akrevia Therapeutics, a privately-held biopharma that was launched in September 2018 by Atlas and F-Prime, has now named its first chief executive.
The Boston-based company, focused on developing highly-potent, tumor-targeted immuno-oncology (I-O) therapeutics, has handed the top job to experienced biotech leader, René Russo (pictured above).
Dr Russo has spent more than 20 years working in pharmaceutical research and development, including executive leadership roles spanning early clinical research through successful commercialization.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze